AC Hotel South SF Oyster Point
1333 Veterans Blvd.
South San Francisco, CA CA, 94080
Speakers are Allison Moore, PhD, Chief Technical Officer, Allogene Therapeutics and Robert Kiss, PhD, Vice President, Process and Analytical Development, Sutro Biopharma, Inc.
See Event Flyer for Details.
Allison Moore, PhD
Chief Technical Officer
Dr. Moore is in charge of overseeing product sciences, supply chain, manufacturing, quality and technical operations. She has extensive experience in biomanufacturing and CMC product development, working in both Operations and Research and Development. She most recently served as Senior Vice President, Process Development at Amgen. Dr. Moore has previously held senior roles at Amgen in Operations Technology, Process and Product engineering, and Corporate Manufacturing. Prior to these positions, she was Vice President, Site Operations at Amgen's Fremont manufacturing facility. Before joining Amgen, Dr. Moore was a Director in Chemistry, Manufacturing and Controls, and Regulatory Affairs at Genentech.
Dr. Moore holds a PhD in Cell Biology from Manchester University, England, and a bachelor’s in Pharmacology with Honors from Manchester University, England. She was a Postdoctoral Research Fellow at the Medical University of Lübeck, Germany, and at Genentech.
Robert Kiss, PhD
Vice President, Process and Analytical Development
Sutro Biopharma, Inc.
Dr. Robert Kiss has over 26 years of process development and manufacturing experience in the biotechnology industry. He came to Sutro after working at Genentech for nearly 24 years, where he most recently held the role of Distinguished Engineer and Senior Director of Late Stage Cell Culture process development. While at Genentech, he was directly involved in the development and initial licensure of the cell culture processes for Rituxan®, Herceptin®, Perjeta®, Tecentriq®, and Ocrevus™, the design and startup of the Vacaville manufacturing sites, and the transfer of multiple cell culture processes to Genentech/Roche and partner sites around the world.
He is globally-recognized for expertise in bioprocess scale-up, glycosylation of CHO-derived recombinant proteins, and virus barriers to protect mammalian cell culture processes. He received his chemical engineering degrees from UC Davis (BS) and the Massachusetts Institute of Technology (MS, PhD), is a Fellow in the American Institute of Medical and Biological Engineering, and is a licensed engineer in the state of California.
Senior Vice President and Chief Financial Officer
Kathy Yi has been with Sangamo for two years. She was formerly with Novartis Pharmaceuticals where she served as Head of Finance, Inhalation Technical Research & Development, responsible for the financial management of technical R&D organizations in California and Switzerland. Prior to joining Novartis, she was with Life Technologies Corp. from 2007 to 2014, during which time she held financial management positions of increasing seniority, including Finance Leader, Corporate FP&A. Prior to joining Life Technologies, Ms. Yi held various positions in finance at Intel Corp., from 2001 to 2007. She began her career as a Process/Project Engineer at Bechtel Corp., a leading global engineering, construction and project management company.
She received a BS degree in Chemical Engineering from the University of California at Berkeley and an MBA degree from Columbia Business School.
The ISPE Programs committee is developing a late afternoon/early evening event to provide our Members with an overview of the latest developments and trends in the local biotech hub.
Allison Moore, PhD, CTO for Allogene Therapeutics and Robert Kiss, PhD, VP Process and Analytical Development at Sutro Biotherapeutics have kindly given up their time to spend with our community of Pharmaceutical Engineers to share their meaningful and personalized stories that speak to the state of the industry.
This event will explore ideas on why South San Francisco is such a hot market for latest trends in novel biotechnologies, what this means for emerging technologies and what effect the market and new emerging technologies will have for the young, modern Bay Area work force.